Type 2 diabetes and Alzheimer’s Disease (AD) are common and concerning public health issues that share several metabolic characteristics such as insulin resistance, mitochondrial defects and oxidative stress. Evidence shows that type 2 diabetes significantly increases the risk of Alzheimer’s disease, with a current paper reporting that the risk of developing Alzheimer’s disease if you have type 2 diabetes is as high as 50%. This paper provides an overview of the metabolic characteristics that link these two conditions with a focus on mitochondria. More importantly, it explores existing therapies that help prevent mitochondrial damage which in turn will help prevent AD and cognitive decline.
Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive decline and dementia, particularly AD. Here, we provide an overview of the metabolic defects that characterize and link both pathologies putting the focus on mitochondria. The biomarker potential of mitochondrial components and the therapeutic potential of some drugs that target and modulate mitochondria are also briefly discussed.
Article Publication Date: 7/4/2023